Carlos Alberto Valdes

Carlos Alberto Valdes

Auto-generated profile, based on publicly available information

Carlos Alberto Valdes

Division of Cardiovascular Surgery, University of Florida, Gainesville, FL, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
TCTeja Chakrala
Teja Chakrala
RPRoshni Prakash
Roshni Prakash
CVCarlos Valdes
Carlos Valdes
CPCarl J Pepine
Carl J Pepine
EKEllen C. Keeley
Ellen C. Keeley
Coronary microvascular dysfunction is an underdiagnosed pathologic process that is associated with adverse clinical outcomes. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in the diagnosis and management of coronary microvascular dysfunction. We present an updated review of circulating biomarkers in coronary microvascular dysfunction representing key pathologic processes, including inflammation, endothelial dysfunction, oxidative stress, coagulation, and other mechanisms.

27 November 2023 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Verified
Journal Article
Closed access
CVCarlos Alberto Valdes
Carlos Alberto Valdes
GSGriffin Stinson
Griffin Stinson
OSOmar M. Sharaf
Omar M. Sharaf
FCFabian Jimenez Contreras
Fabian Jimenez Contreras
ABAhmet Bilgili
Ahmet Bilgili
EJEric I. Jeng
Eric I. Jeng
Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is approved by the US Food and Drug Administration (FDA) for mechanical circulatory support for ≤14 days. It is unknown whether prolonged support is associated with worse outcomes. We sought to review our single-center experience with Impella 5.5 and compare outcomes based on support duration. Methods: We retrospectively reviewed adult patients (≥18 years old) supported with Impella 5.5 at our institution (May 2020 to April 2023). Patients on prolonged support (>14 days) were compared with those supported for ≤14 days. Results: There were 31 patients supported with Impella 5.5 including 14 (45.2%) supported >14 days. Median support duration for those on prolonged support was 43.5 (interquartile range [IQR] 25 to 63.5) days versus 8 (IQR 6, 13) days for those who were not ( P < 0.001). Overall, the device-related complication rate was 9.7% and did not differ between groups ( P = 0.08). Overall, 30-day postimplant survival was 71% and did not differ by support duration ( P = 0.2). In-hospital mortality was 32% and did not differ between cohorts ( P > 0.99). Among those surviving to explant ( n = 22), long-term strategy included bridge to durable ventricular assist device (18%, n = 4), cardiac transplant (55%, n = 12), and cardiac recovery (27%, n = 6). Conclusions: High-risk patients with cardiogenic shock may be supported with Impella 5.5 beyond the FDA-approved duration without increased risk of complications or mortality.

1 July 2024 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Verified
Journal Article
Closed access
CVCarlos Alberto Valdes
Carlos Alberto Valdes
ABAhmet Bilgili
Ahmet Bilgili
ARAkshay Reddy
Akshay Reddy
OSOmar Sharaf
Omar Sharaf
FJFabian Jimenez-Contreras
Fabian Jimenez-Contreras
EJEric I. Jeng
Eric I. Jeng
Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device’s clinical effectiveness, safety profile, patient outcomes, and relevant procedural considerations. Methods: We conducted a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the PubMed/MEDLINE database. The search query included articles available from October 6, 2022, through January 13, 2023. Our initial search identified 75 studies. All records were screened by 2 independent reviewers using the Covidence software for adherence to our inclusion criteria, and 8 retrospective cohort studies were identified as appropriate for inclusion. Results: Across the included studies, the sample size ranged from 4 to 275, with predominantly male cohorts. Indications for Impella support varied, and the duration of support ranged from 9.8 to 70 days. Overall, Impella support appeared to be associated with favorable survival rates and manageable complications in various patient populations. Complications associated with Impella use included bleeding, stroke, and device malfunctions. Two studies compared prolonged and Food and Drug Administration–approved Impella support, showing similar outcomes and adverse events. Conclusions: Impella 5.5 continues to be an attractive option for bridging patients to definitive therapy. Survival during and after Impella 5.5 was favorable for patients regardless of initial indication. However, device use was associated with several important complications, which calls for judicious use and a precontemplated exit strategy. Limitations of this literature review include biases inherent to the retrospective studies included, such as selection and publication bias.

1 April 2021 in Taiwan Journal of Ophthalmology
Verified
Journal Article
Open access
CPCarlos F. Peñaranda
Carlos F. Peñaranda
DADhariana Acon
Dhariana Acon
CVCarlos A. Valdes
Carlos A. Valdes
LWLihteh Wu
Lihteh Wu
The aim of the study was to describe the ocular findings following an accidental high-voltage electrical discharge. A 32-year-old male suffered an accidental electric discharge of 10,000 volts of direct current. He developed cortical, nuclear, and posterior subcapsular opacities in both the eyes. The retinal examination showed bilateral macular cysts. Four months after the event, the macular cyst in the OD spontaneously regressed without visual improvement. The macular cyst in the OS remained unchanged. High-voltage electrical discharge can lead to bilateral maculopathy and cataracts. The visual prognosis is reserved. The visual acuity may not improve despite macular cyst regression.

17 March 2025 in Artificial Organs
Verified
Journal Article
Closed access
CVCarlos Alberto Valdes
Carlos Alberto Valdes
KDKristin Drew
Kristin Drew
OSOmar M. Sharaf
Omar M. Sharaf
MAMustafa M. Ahmed
Mustafa M. Ahmed
APAlex M. Parker
Alex M. Parker
MAMohammad A. Z. Al‐Ani
Mohammad A. Z. Al‐Ani

19 June 2025 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Verified
Journal Article
Closed access
GSGriffin P. Stinson
Griffin P. Stinson
CVCarlos A. Valdes
Carlos A. Valdes
ABAhmet Bilgili
Ahmet Bilgili
LKLiam Kugler
Liam Kugler
FCFabian Jimenez Contreras
Fabian Jimenez Contreras
JSJohn R. Spratt
John R. Spratt
Objective: Open aortic repair is considered the standard of care for patients with connective tissue disease (CTD) due to the perceived durability advantages compared with endovascular intervention. However, some complex CTD patient presentations increase risk with open repair, favoring endovascular intervention. This analysis sought to review our experience with endovascular intervention in CTD patients and identify scenarios in which this approach may reasonably be considered. Methods: Patients with CTD undergoing endovascular intervention at our institution from 2006 to 2023 were retrospectively reviewed. The primary outcome was freedom from aorta-related mortality. Secondary outcomes included all-cause mortality and freedom from secondary intervention. Results: Forty-five CTD patients underwent endovascular intervention. Thirty-five patients (77.8%) had at least 1 previous aortic intervention. Urgent or emergent presentation was common ( n = 31, 68.8%). At index hospitalization, 32 patients (71.1%) underwent thoracic endovascular aortic repair, and 6 patients (13.3%) underwent fenestrated and/or branched endovascular repair. Aneurysm ( n = 40, 88.9%) and dissection ( n = 36, 80.0%) were the most common indications; many patients ( n = 31, 68.9%) presented with both. Freedom from aorta-related mortality was 88.7% ± 5% and 83.2% ± 6% at 1 and 3 years, respectively. No clinical or procedural factors were predictive of aorta-related mortality. Twenty-one patients (46.7%) required secondary intervention; the median time to secondary intervention was 6.5 months (6.5, 18.9 months). Freedom from secondary intervention was 60.0% ± 8% and 51.4% ± 9% at 1 and 3 years, respectively. Conclusions: Endovascular intervention is often lifesaving in CTD patients who are not initially candidates for open repair. Aorta-related mortality was low, and fewer than half of patients required secondary intervention during the study period. This illustrates the utility of endovascular intervention in bridging CTD patients to definitive open repair.